关键词: 慢性肝病, 异甘草酸镁, 治疗

Abstract: Objective To investigate the improvement of laboratory index by magnesium isoglycyrrhizinate （MIG） in patients with chronic liver diseases. Methods 66 patients with chronic liver diseases were treated with MIG and 129 with non-glycyrrhizic acids（non-MIG）,such as with diisopropylamine dichloroacetate alone or combined with one or two kinds of hepatoprotective agents. Clinical data and laboratory results were analysed,such as the changes of blood hematology,electrolytes,coagulation and liver biochemistry for two weeks. Results Compared with non-MIG,MIG was mainly used in DILI patients（42.4% vs 5.4%,P<0.01）;In MIG group,the level of the white blood cell（P=0.01） and platelet（P<0.01） elevated after the first week of the treatment,and the liver enzyme （ALT,AST,ALP,and GGT） decreased significantly（P<0.01）;At the initiation of the treatment,the levels of ALT,AST,GGT and ALP in MIG therapy group were 5-fold （P<0.01）,2.94-fold （P<0.01）,2.41-fold（P<0.01） and 1.63-fold（P<0.01） higher than non-MIG group,respectively. After the two-week-treatment,they decreased to 1.53-fold（P=0.03）,1.04-fold （P=0.79）,1.29-fold （P=0.26） and 1.1-fold （P=0.33）,respectively;There were almost no effects on electrolytes and coagulation indexes in MIG group（P>0.05,respectively）;After two week treatment,there were no significant differences between TP,ALB,and Hb in the two groups（P>0.05,respectively）. Conclusion MIG treatment is safe and effective in patients with chronic liver injury. Compared to the control group,enzymatic indicators in MIG group shows a quick recovery and no significant side effects.

Key words: Chronic liver diseases, Magnesium isoglycyrrhizinate, Treatment